RCS - Cambridge Cognition - Investor Presentation
RNS Number : 8680RCambridge Cognition Holdings PLC11 March 2021Cambridge Cognition Holdings plc
("Cambridge Cognition" or the "Company")
Investor Presentation
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that CEO Matthew Stork and CFO Michael Holton will provide a live investor presentation on Tuesday 23 March at 6.00 p.m. London time. This follows the anticipated release of the Company's preliminary results for the year ended 31 December 2020 at 7:00 a.m. on 23 March 2021.
The presentation is open to all existing and potential shareholders. Those wishing to attend should email cog@investor-focus.co.uk and they will be provided with log in details. There will be the opportunity for participants to ask questions at the end of the presentation. Questions can also be emailed to the above address ahead of the presentation.
Enquiries:
Cambridge Cognition Holdings PLC
Matthew Stork, Chief Executive Officer
Michael Holton, Chief Financial Officer
Tel: 012 2381 0700
finnCap Ltd (NOMAD and Joint Broker)
Geoff Nash / Simon Hicks
Alice Lane / Charlotte Sutcliffe
Tel: 020 7220 0500
(Corporate Finance)
(Corporate Broking)
Dowgate Capital Limited (Joint Broker)
David Poutney / James Serjeant
Tel: 020 3903 7715
IFC Advisory Ltd (Financial PR and IR)
Tim Metcalfe / Graham Herring / Zach Cohen
Tel: 020 3934 6630
cog@investor-focus.co.uk
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDNRAJMMPTMTTBBPB
Recent news on Cambridge Cognition Holdings
See all newsREG - Cambridge Cognition - Preliminary Results, Trading Update & Board Change
AnnouncementREG - Cambridge Cognition - Notice of Results
AnnouncementREG - Cambridge Cognition - COG spin-out Monument Therapeutics accesses £1.5m
AnnouncementREG - Cambridge Cognition - Total Voting Rights and Block Listing Return
AnnouncementREG - Cambridge Cognition - Formation of new Scientific Advisory Board
Announcement